Per a Reuters article, Credit Suisse CS was able to put behind three pending lawsuits that charged it of having mislead investors regarding a complex product — VelocityShares Daily Inverse VIX Short-Term Exchange-Traded Notes (XIV Notes).
XIV Notes — a popular product offered by the bank — were linked to expectations of future price swings. The notes were designed to produce opposite returns of Cboe Volatility Index, thus these sank more than 90% following a market selloff in February 2018, post which Credit Suisse took the product off market.
Investors filed a lawsuit against the bank stating that it manipulated the notes by liquidating its holdings in various financial products to avoid a loss. It also said the company’s statements about the product to investors were incomplete.
The U.S. District judge dismissed the cases stating the company had sufficiently warned investors about the downsides involved in these notes. Also, it was ruled that Credit Suisse’s move to purchase a huge bunch of futures contracts was backed by no wrong intentions, rather to take advantage of favorable market conditions.
Credit Suisse remains involved in a number of regulatory and legal proceedings. In its latest quarterly filing, the company estimated that the aggregate range of loss not covered by existing litigation provisions could go as high as CHF 1.4 billion.
Nevertheless, Credit Suisse is well poised to reap benefits from the three-year restructuring overhaul it successfully completed in 2018. Also, it continues to bolster its wealth management business by expanding presence.
The stock has gained 12.2% over the past six months against 0.7% decline recorded by the industry it belongs to.
Currently, it flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Stocks to Consider
BNP Paribas SA BNPQY has been witnessing upward estimate revisions for the past 60 days. Moreover, this Zacks #2 Ranked (Buy) stock has rallied 6.2% year to date.
Sumitomo Mitsui Financial Group SMFG has been witnessing upward estimate revisions for the past 60 days. Also, the company’s shares have gained 8.6%, year to date. At present, it carries a Zacks Rank of 2.
The Toronto Dominion Bank TD has been witnessing upward estimate revisions for the past 60 days. Additionally, the stock has rallied around 15% year to date. It currently holds a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BNP Paribas SA (BNPQY) : Free Stock Analysis Report
Sumitomo Mitsui Financial Group Inc (SMFG) : Free Stock Analysis Report
Toronto Dominion Bank (The) (TD) : Free Stock Analysis Report
Credit Suisse Group (CS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research